VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

26th June 2012 - News release

LCIG CLINICAL TRIAL RESULTS FOR PARKINSON'S DISEASE

Levodopa-carbidopa is administered in gel form, directly into the small intestine via a procedurally-implanted tube connected to a portable pump that delivers continuous supply of LCIG during waking hours. LCIG is currently approved in 40 countries. In the U.S.A., LCIG is an investigational therapy that is currently being evaluated in patients with advanced Parkinson's disease in additional Phase 3 clinical trials. Abbott have announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), concerning a 54 week open-label safety and tolerability study of people with advanced Parkinson's disease. The efficacy of LCIG was compared to that of standard levodopa-carbidopa immediate release, which is the same as Sinemet. There was nearly 2 hours less off time with LCIG.

The most common adverse events were complication of device insertion (33%), abdominal pain (30%), procedural pain (21%) and nausea (16%). The most common serious adverse events were complication of device insertion (6%), abdominal pain (3%) peritonitis (3%) and polyneuropathy (3%). 7% of patients withdrew due to at least one adverse event. In another clinical trial the most common adverse events were complication of device insertion (51%), abdominal pain (42%), procedural pain (32%), nausea (25%), constipation (21%), orthostatic hypotension (18%), post-operative wound infection (17%), and incision site erythema (16%).

For the full details go to the News release  For a printable version of this article click hereFor more current news go to Parkinson's Disease News.

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports

                                    

 

 
2006-2012  Viartis
 
2015-09-04 03:09:39
 
[email protected]